/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
+0.28%
Natural Gas
0.00%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-0.46%
VIX
N/A
Economic Calendar
EUR/USD
+0.28%
Natural Gas
0.00%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-0.46%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
Bank of Japan Monetary Policy Decision Sends the USD/JPY to 156
about 3 hours ago
Tech Giants Excel: Alphabet’s Dividend, Microsoft’s AI Growth, Snap’s Q1 Surge
about 10 hours ago
Microsoft and Alphabet Bracing for Key Earnings Release
about 12 hours ago
Pending Home Sales Increased 3.4% In March, Beating Analyst Expectations
about 16 hours ago
US GDP Growth Starts 2024 Below Expectations
about 16 hours ago
German GfK Consumer Climate Indicator Climbs to -24.2 for May
1 day ago
Gold (XAU) Daily Forecast: XAU Nears $2,335; More Upside Ahead?
13 minutes ago
Natural Gas and Oil Forecast: Tensions Spike Prices; Will Oil Stay Bullish?
about 1 hour ago
DAX Index Today: ECB Chatter, Corporate Earnings and US Inflation
about 2 hours ago
Bitcoin (BTC) News Today: Analyzing BTC-Spot ETF Flows Amid US Economic Reports
about 2 hours ago
XRP News Today: SEC Given Three Days to Counter Ripple’s Motion to Strike
35 minutes ago
AUD to USD Forecast: Aussie Inflation Data Pivotal for RBA Interest Rate Outlook
about 7 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
ACAD
profile
Acadia Pharmaceuticals Inc
Follow
ACAD
(
Nasdaq - US
)
N/A
16.33
-0.26 (-1.57%)
in
:
usd
•
As of: Apr 25, 2024 15:59
UTC -4
Open
16.39
High
16.50
Low
16.16
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Acadia Pharmaceuticals Inc
CEO
Stephen R. Davis
Headquarters
12830 el camino real,suite 400
san diego, ca 92130, united states
Auditor
Ernst & Young LLP
Employees
598
Share Holders
34
Website
www.acadia pharm.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as?dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.
Acadia Pharmaceuticals Inc
Statistics
Valuation Measures
Market Capitalization
2
2.69B
Enterprise Value
2.50B
Enterprise Value/EBITDA
(ttm)
-33.20
Price to Earnings Ratio
(ttm)
N/A
Price to Book
(mrq)
6.37
Price to Sales
(ttm)
3.80
Price to Cash
(ytd)
N/A
Profitability
Gross Margin
(ttm)
94.86%
Operating Margin
(ttm)
-8.44%
Profit Margin
(ttm)
-11.65%
Return on Equity
(ttm)
-15.67%
Return on Invested Capital
(ttm)
-18.60%
Return on Assets
(ttm)
-9.15%
Income Statement
Revenue
(ttm)
726.44M
Revenue Per Share
(ttm)
4.41
Gross Profit
(ttm)
684.80M
EBITDA
(ttm)
3
-75.36M
Net Income Avi to Common
(ttm)
-61.29M
Diluted EPS
(ttm)
-0.38
Share Statistics
Beta (5Y Monthly)
0.37
52-Week Change
-19.60%
S&P500 52-Week Change
24.47%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
164.77M
Dividend Yield
0.00%
Float
4
119.46M
%
Held by Insiders
27.50%
%
Held by Institutions
96.71%
Balance Sheet
Total Cash
(mrq)
438.87M
Total Cash Per Share
(mrq)
2.66
Total Debt
(mrq)
0.00
Total Debt/Equity
(mrq)
0.00%
Current Ratio
(mrq)
2.42%
Quick Ratio
(mrq)
2.28%
Book Value Per Share
(mrq)
2.62
Cash Flow
Operating Cash Flow Per Share
(ytd)
0.10
Free Cash Flow
(ytd)
16.65M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker